Profile data is unavailable for this security.
About the company
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
- Revenue in USD (TTM)38.30m
- Net income in USD-134.81m
- Incorporated2001
- Employees123.00
- LocationMersana Therapeutics Inc840 Memorial DrCAMBRIDGE 02139-3789United StatesUSA
- Phone+1 (617) 498-0020
- Fax+1 (302) 655-5049
- Websitehttps://www.mersana.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rezolute Inc | 0.00 | -58.21m | 216.32m | 51.00 | -- | 2.38 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 217.12m | 135.00 | -- | 8.13 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 218.41m | 133.00 | -- | 1.18 | -- | 205.27 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 218.43m | 122.00 | -- | 2.09 | -- | 304.61 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Zura Bio Ltd | 0.00 | -60.18m | 218.44m | 14.00 | -- | 2.45 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
ESSA Pharma Inc | 0.00 | -27.73m | 218.71m | 50.00 | -- | 1.64 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Omeros Corp | 0.00 | -179.09m | 223.09m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Vicapsys Life Sciences Inc | 0.00 | -1.08m | 225.46m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Mersana Therapeutics Inc | 38.30m | -134.81m | 227.59m | 123.00 | -- | 8.13 | -- | 5.94 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Renovaro Inc | 0.00 | -53.93m | 228.63m | 11.00 | -- | 1.36 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Solid Biosciences Inc | 0.00 | -90.25m | 228.74m | 88.00 | -- | 1.07 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Tectonic Therapeutic Inc | 0.00 | 30.31m | 233.39m | 13.00 | 1.91 | 0.6669 | 7.63 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Tenaya Therapeutics Inc | 0.00 | -124.58m | 233.59m | 140.00 | -- | 1.48 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Eliem Therapeutics Inc | 0.00 | -14.53m | 235.97m | 9.00 | -- | 1.77 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Black Diamond Therapeutics Inc | 0.00 | -79.79m | 236.82m | 54.00 | -- | 2.12 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 19.36m | 15.83% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 7.24m | 5.92% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.09m | 4.98% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.50m | 4.49% |
Balyasny Asset Management LPas of 31 Mar 2024 | 3.66m | 2.99% |
Rock Springs Capital Management LPas of 31 Mar 2024 | 3.05m | 2.49% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.01m | 2.46% |
SilverArc Capital Management LLCas of 31 Mar 2024 | 2.97m | 2.43% |
Woodline Partners LPas of 31 Mar 2024 | 2.93m | 2.40% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.93m | 2.40% |